Yiling Pharmaceutical's LB220-D08 Extended-Release Tablets Clinical Trial Application Accepted
Yiling Pharmaceutical announced in a filing that its clinical trial application for the innovative drug LB220-D08 extended-release tablets has been formally accepted. The drug is intended for the treatment of atypical hemolytic uremic syndrome (aHUS). With the application accepted, the company can proceed with clinical development of the candidate for this indication, subject to further regulatory requirements and ongoing review.
Yiling Pharmaceutical announced that its clinical trial application for the innovative drug LB220-D08 extended-release tablets has been accepted. The drug's indication is atypical hemolytic uremic syndrome (aHUS).
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Biotechnology, with intensity 20/100 and 30% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.